References
- Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1-14.
- Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-98. https://doi.org/10.1093/brain/awm111
- Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730-6. https://doi.org/10.1212/WNL.56.6.730
- Cheng N, Maeda T, Kume T, et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996; 743: 278-83. https://doi.org/10.1016/S0006-8993(96)01056-6
- Bianchine JR. Drug therapy of parkinsonism. N Engl J Med 1976; 295: 814-8. https://doi.org/10.1056/NEJM197610072951505
- Ludin HP, Bass-Verrey F. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor. J Neural Transm 1976; 38: 249-58. https://doi.org/10.1007/BF01249442
- Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292-6.
- Marttila RJ. Diagnosis and epidemiology of Parkinson's disease. Acta Neurol Scand Suppl 1983; 95: 9-17.
- Cunha CD, Angelucci MEM, Canteras NS, et al. The lesion of the rat substantianigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002; 22: 227-37. https://doi.org/10.1023/A:1020736131907
- Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584-94. https://doi.org/10.1093/brain/awf052
- Cheng N, Maeda T, Kume T, et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996; 743: 278-83. https://doi.org/10.1016/S0006-8993(96)01056-6
- Jin CM, Yang YJ, Huang HS, et al. Induction of dopamine biosynthesis by l-DOPA in PC12 cells: implications of L-DOPA influx and cyclic AMP. Eur J Pharmacol 2008; 591: 88-95. https://doi.org/10.1016/j.ejphar.2008.06.052
- Murphy DL, Henry GM, Weingartner H. Catecholamines and Memory: Enhanced verbal learning during L-DOPA administration. Psychopharmacologia 1972; 27: 319-26. https://doi.org/10.1007/BF00429385
- Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: The role of the prefrontal cortex revealed by PET. Brain 2002: 125: 584-94. https://doi.org/10.1093/brain/awf052
- Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002; 23(1-3):57-63. https://doi.org/10.1007/s00726-001-0110-x
- Lacy CF, Amstrong LL, Goldman MP, et al. (2009-2010) Drug information handbook 18th ed : Lexi-Comp Inc.
- Shulman LM, Taback RL, Bean J, et al. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16: 507-10. https://doi.org/10.1002/mds.1099
- Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42. https://doi.org/10.1136/jnnp.2005.083113
- Han IT, Ha CK, Hong CG, et al. Behavioral and psychological symptoms in patients with Parkinson's disease according to cognitive function. Dementia and Neurocognitive Disorders 2012; 11: 104-10. https://doi.org/10.12779/dnd.2012.11.3.104
- Kim JW, Cheon SM, Park MJ, et al. Cognitive impairment in Parkinson's disease without dementia: subtypes and influences of age. J Clin Neurol 2009; 5: 133-8. https://doi.org/10.3988/jcn.2009.5.3.133
- Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707. https://doi.org/10.1002/mds.21507
- Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83: 1253-60. https://doi.org/10.1212/WNL.0000000000000842
- Wang Q, Zhang Z, Li L, Wen H, et al. Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors. Clin Interv Aging 2014; 9: 275-81.
- Rosdinom R, Fazli A, Ruzyanei NJ, et al. Factors associated with cognitive impairment in patients with Parkinson disease: an urban study. Clin Ter 2011; 162: 23-9.
- Hietanen M, Teravainen H. Dementia and treatment with L-dopa in Parkinson's disease. Mov Disord 1988; 3: 263-70. https://doi.org/10.1002/mds.870030311
- Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596-602. https://doi.org/10.1212/WNL.54.8.1596
- Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730-6. https://doi.org/10.1212/WNL.56.6.730
- Zhu K, van Hilten JJ, Marinus J. Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPACOG. Parkinsonism Relat Disord 2014; 20: 980-5. https://doi.org/10.1016/j.parkreldis.2014.06.006